Oppenheimer Starts Fusion Pharmaceuticals (FUSN) at Outperform, 'Diverse Clinical-Stage Portfolio Positions FUSN as a Radiopharm Leader'
Tweet Send to a Friend
(Updated - September 28, 2023 4:02 PM EDT)
Oppenheimer analyst Jeff Jones initiates coverage on Fusion Pharmaceuticals (NASDAQ: FUSN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Jeff Jones initiates coverage on Fusion Pharmaceuticals (NASDAQ: FUSN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
